β-Lactamase inhibition with clavulanic acid supplementing standard amoxycillin-based triple therapy does not increase Helicobacter pylori eradication rate

Digestive and Liver Disease

Volumn 37, Issue 11, 2005, Pages 826-831

  Crispino, P ^a   Iacopini, F ^a   Pica, R ^a   Consolazio, A ^a   Bella, A ^c   Cassieri, C ^a   Nardi, F ^b   Paoluzi, P ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Higher Institute of Health   (Italy)

Author keywords

Amoxycillin; Antibiotic resistance; Clavulanic acid; Helicobacter pylori

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CLARITHROMYCIN; ESOMEPRAZOLE; CLAVULANIC ACID; ENZYME INHIBITOR;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIGEN DETECTION; ARTICLE; BACTERIAL STRAIN; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; ENZYME INHIBITION; ERADICATION THERAPY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL INFECTION; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TASTE DISORDER; TREATMENT DURATION; UREA BREATH TEST; VOMITING; DRUG EFFECT; ENZYMOLOGY; FECES; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS;

AMOXICILLIN; BETA-LACTAMASES; CLAVULANIC ACID; ENZYME INHIBITORS; FECES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 33644875440     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.07.010     Document Type: Article

References (37)

1. Malfertheiner P., Megraud F., O'Morain C., Hungin APS, Jones R., Axon A., et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180
2. Bazzoli F., Porro G., Bianchi M.G., Molteni M., Pozzato P., and Zagari R.M. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis 34 (2002) 70-83
3. Perri F., Villani M.R., Festa V., Quitadamo M., and Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 15 (2001) 1023-1029
4. Bazzoli F., Olivieri L., De Luca L., Pozzato P., Lehours P., and Megraud F. Therapy and drug resistance in Helicobacter pylori infection. Dig Liver Dis 32 (2000) S207-S210
5. Pilotto A., Rassu M., Leandro G., Franceschi M., and Di Mario F. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 32 (2000) 763-768
6. Pilotto A., Leandro G., Franceschi M., Rassu M., Bozzola L., Furlan F., et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 13 (1999) 667-673
7. Realdi G., Dore M.P., Piana A., Atzei A., Carta M., Cugia L., et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 4 (1999) 106-112
8. Boyanova L., Mentis A., Gubina M., Rozynek E., Gosciniak G., Kalenic S., et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Europe. Clin Microbiol Infect 8 (2002) 388-396
9. Xiao S.D., Liu W.Z., Hu P.J., Ouyang Q., Wang J.L., Zhou L.J., et al. A multicentre study on eradication of H. pylori in patients using four 1-wk triple therapies in China. Aliment Pharmacol Ther 15 (2001) 81-86
10. O'Morain C., and Montague S. Challenges to therapy in the future. Helicobacter 5 (2000) S23-S26
11. Mendonca S., Ecclissato C., Sartori MS., Godoy A.P.O., Guerzoni R.A., Degger M., et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline, and furazolidone in Brazil. Helicobacter 5 (2000) 79-83
12. Horii T., Kimura T., Sato-Kawamura K., Nada T., Shibayama K., and Ohta M. β-Lactamase inhibitors have antibacterial activities against Helicobacter pylori. J Infect Chemother 5 (1999) 206-207
13. Vcev A., Vceva A., Takac B., Dmitrovic B., Stimac D., Stimac T., et al. Omeprazole, azithromycin and amoxycillin or amoxycillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. Acta Med Croatica 52 (1998) 209-214
14. Ojetti V., Migneco A., Zocco M.A., Nista E.C., Gasbarrini G., and Gasbarrini A. Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate. J Intern Med 255 (2004) 125-129
15. Cutler A.F., and Schubert T.T. Patient factors affecting H. pylori eradication with triple therapy. Am J Gastroenterol 88 (1993) 505-509
16. Romano M., Iovene M.R., Montella F., Vitale L.M., De Simone T., and Del Vecchio Blanco C. Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection. Am J Gastroenterol 95 (2000) 3317-3318
17. Gisbert J.P., Marcos S., Gisbert J.L., and Pajares J.M. Helicobacter pylori eradication is more effective in peptic ulcer than in non-ulcer dyspesia. Eur J Gastroenterol Hepatol 13 (2001) 1303-1307
18. De Boer W.A., and Tytgat G.N.J. Should anti-Helicobacter pylori therapy be different in patients with dyspepsia compared with patients of peptic ulcer diathesis?. Eur J Gastroenterol Hepatol 13 (2001) 1281-1284
19. Van der Hulst R.W., van der Hende A., Dekker F.W., Ten Kate F.J.W., Weel J.F.L., Keller J.J., et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-years follow-up study. Gastroenterology 113 (1997) 25-30
20. Van Doorn L.J., Schneeberger P.M., Nouhan N., Plaiser A.P., Quint WGV, and de Boer W.A. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotics treatment. Gut 46 (2000) 321-326
21. Labenz J., Leverkus F., and Borsch G. Omeprazole plus amoxycillin for cure of Helicobacter pylori infection. Factor influencing the treatment success. Scand J Gastroenterol 29 (1994) 1070-1075
22. Laurent J., Megraud F., Flejou J.F., Caekaert A., and Barthelemy P. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 15 (2001) 1787-1793
23. Gumurdulu Y., Serin E., Ozer B., Kayaselcuk F., Ozsahin K., Cosar A.M., et al. Low eradication rate of Helicobacter pylori with 7-14 days and quadruple therapy in Turkey. World J Gastroenterol 10 (2004) 668-671
24. Altintas E., Sezgin O., Ulu O., Aydin O., and Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 10 (2004) 1656-1658
25. Kwon D.H., Dore M.P., Kim J.J., Kato M., Lee M., Wu J.Y., et al. High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother (2003) 2169-2178
26. Laheij R.J., Rossum L.G., Jansen J.B., Straatman H., and Verbeek L. Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta analysis. Aliment Pharmacol Ther 13 (1999) 857-864
27. Ling T.K., Cheng A.F., Sung J.J., Yiu P.Y., and Chung S.S. An increase in H. pylori strains resistant to metronidazole: a five-year study. Helicobacter 1 (1996) 57-61
28. Osato M.S., Reddy R., and Graham D.J. Metronidazole and clarithromycin resistance amongst H. pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 12 (1999) 341-347
29. Goddard A.F., and Spiller R.C. Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Aliment Pharmacol Ther 10 (1996) 1009-1013
30. Calabrese C., Di Febo G., Areni A., Scialpi C., Biasco G., and Miglioli M. Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of H. pylori infection. Aliment Pharmacol Ther 14 (2000) 1613-1617
31. Bertoni G., Sassatelli R., Nigrisoli E., Tansini P., Bianchi G., Della Casa G., et al. Triple therapy with azithromycin, omeprazole and amoxycillin is highly effective in the eradication of H. pylori: a controlled trial versus omeprazole plus azithromycin. Am J Gastroenterol 91 (1996) 258-263
32. Caselli M., Trevisani L., Tursi A., Sartori S., Ruina M., Luzzi I., et al. Short-term low dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of H. pylori. Eur J Gastro Hepatol 9 (1997) 45-48
33. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 11 (1997) 43-53
34. Kamada T., Haruma K., Komoto K., Mihara M., Chen X., Yoshihara M., et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxycillin and clarithromycin. Helicobacter 4 (1999) 204-210
35. Hollanders D., Morrissey S.M., and Ward P.M. Histochemistry of gastric mucins in smokers and non-smokers. Br J Clin Pract 40 (1986) 74-77
36. Georgopoulos S.D., Ladas S.D., Karatapanis S., Mentis A., Spiliadi C., Artikis V., et al. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxycillin and clarithromycin. Dig Dis Sci 45 (2000) 63-67
37. Vaira D., Malfertheiner P., Megraud F., Axon A.T., Deltenre M., Gasbarrini G., et al. Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The European Helicobacter pylori HpSA Study Group. Am J Gastroenterol 95 (2000 Apr) 925-929